CMS Prioritizes IRA Implementation and PBM Reform in Drug Pricing Agenda
The Trump administration has placed drug pricing at the top of its health policy agenda, with CMS focusing on implementing Inflation Reduction Act provisions and pursuing pharmacy benefit manager reforms. The agency is working on Medicare price negotiation, inflation rebates, and Part D redesign while exploring PBM transparency and reform measures. These initiatives affect how Medicaid managed care organizations negotiate drug prices, manage pharmacy benefits, and coordinate with Medicare for dual-eligible beneficiaries. The timeline for specific regulatory actions remains under development.
Medicaid MCOs must align pharmacy benefit management strategies with evolving federal drug pricing rules, particularly for dual-eligible populations where Medicare and Medicaid coverage intersect.
Pharmacy · Managed Care · Finance
You might also like